JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Rilmenidine phosphate is the water soluble form of Rilmenidine. It is an antihypertensive drug targets the imidazoline receptor. [1]Imidazoline receptor is a family of non-adrenergic high affinity binding site for clonidine, idazoxan, and other imidazoline drugs. [2] There are three types of imidazoline receptor. I-1 mediates sympatho-inhibitory actions to the lower blood pressure; I-2 is allosteric binding site of monamine oxidase and I-3 controls insulin secretion of pancreatic cells. [3]In Hep G2 cells treated with 0.5 mM oleic acid for 6 hours and 1μm Rilmenidine for 30 minutes, the oleic acid-induced lipid accumulation decreases. [4] Stimulation of imidazoline I-1 receptor by Rilmenidine activated P38 to induce the expression of FXR. [4]Mice fed with HFD (high fat diet) had improved hepatic steatosis following the administration of Rilmenidien through the activation of imidazoline I-1 receptor. [4] Imidazoline receptors are involved in the bulbospinal regulation of blood pressure and affect peripheral stimulation. [1] In hypertensive patients, Rilmenidine decreased blood pressure in a dose-dependent mater. In contrast with placebo, Rilmenidine had significantly lowered blood pressures. In addition, Rilmenidine had significantly less incidences of adverse effects than using other drugs for hypertension. [1]References:[1] Laurent S, Safar M. Rilmenidine: a novel approach to first-line treatment of hypertension. Am J Hypertens. 1992 Apr;5(4 Pt 2):99S-105S.[2] Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands.Annu Rev Pharmacol Toxicol. 1996;36:511-44.[3] Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):17-32.[4] Yang PS, Wu HT, Chung HH, Chen CT, Chi CW, Yeh CH, Cheng JT. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):51-6.